Stockscreener 앱 받기
25.90
1.97%
0.50
전일 마감가:
$25.40
열려 있는:
$25.71
하루 거래량:
13.76M
Relative Volume:
1.32
시가총액:
$10.71B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-2.9668
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
-2.89%
1개월 성능:
-7.47%
6개월 성능:
-34.25%
1년 성능:
-80.73%
1일 변동 폭
$25.42
$26.02
1주일 범위
$25.06
$26.75
52주 변동 폭
$23.15
$138.07
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.90 | 10.71B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
BDF Gestion Invests $783,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mRNA pioneer’s stock faces pivotal moment - Investing.com
Trump administration cancels Moderna contract to fight bird flu and other viruses - Arizona Daily Star
Moderna (MRNA) Sees Bullish Trading Activity with Increased Options Volume | MRNA Stock News - GuruFocus
US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract - MarketScreener
Zika Virus Therapeutics Market Size & Share | Industry Growth [2032] - SkyQuest Technology
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine - Benzinga
Moderna (MRNA) Sees Bearish Sentiment Among Option Traders | MRNA Stock News - GuruFocus
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
SG Americas Securities LLC Lowers Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Rakuten Securities Inc. Has $742,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts - Benzinga
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 3.8%Here's What Happened - MarketBeat
Transcript : Moderna, Inc.Special Call - MarketScreener
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Tobam - MarketBeat
Union Bancaire Privee UBP SA Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna | History, Innovation, Challenges, & Facts - Britannica
FDA approves Moderna’s new COVID-19 vaccine - Santa Clarita Valley Signal
FDA approves expanded use of Moderna’s RSV shot - MSN
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo
GAMMA Investing LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mrna stock faces challenges amid vaccine shifts - Investing.com
Here's Why Moderna (MRNA) Fell More Than Broader Market - sharewise
Moderna Seeks Outside Investors to Fund Select Vaccine Trials - MSN
FDA expands approval of Moderna’s RSV vaccine to some adults under age 60 - weisradio.com
FDA expands approval of Moderna's RSV vaccine to some adults under age 60 - WBAL News Radio
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains - The Hill
IBM and Moderna tout use cases for AI in total rewards - HR Brew
Moderna falls on doubts over new CDC panel's backing of RSV vaccine - Reuters
Moderna (MRNA) Faces Challenges Despite RSV Vaccine Approval - GuruFocus
Moderna wins FDA OK to widen use of RSV vaccine - BioPharma Dive
Moderna Stock Falls on CDC Panel Concerns Over RSV VaccineNews and Statistics - IndexBox
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59 - The Boston Globe
Moderna under pressure despite RSV vaccine approval into wider age group - MSN
FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults - The Pharma Letter
Moderna (MRNA) Faces Intensified Short Selling Amid Challenges - GuruFocus
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects - TradingView
Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology - BioSpace
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults - Yahoo Finance
Moderna's RSV shot gets US nod for use in younger adults - pharmaphorum
Moderna (MRNA) Gains FDA Approval for Expanded RSV Vaccine Use - GuruFocus
FDA expands Moderna's RSV vaccine approval to at-risk adults (MRNA:NASDAQ) - Seeking Alpha
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up - Benzinga
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Knoxville News Sentinel
Moderna Gets FDA Approval for mRESVIA in Adults Aged 18-59 at Increased Risk for RSV Disease - marketscreener.com
Moderna (MRNA) Receives FDA Nod for RSV Vaccine Extended Use | M - GuruFocus
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.86%
1.98%
자본화:
|
볼륨(24시간):